Udayavni Special

Pfizer says its Covid-19 vaccine 100% effective on 12 to 15-year-olds


PTI, Mar 31, 2021, 5:05 PM IST

New Delhi: BioNTech-Pfizer said Wednesday their vaccine showed 100 per cent efficacy against the coronavirus in 12 to 15-year-olds, as they eye approval for adolescents to get the jabs before the next school year.

Phase 3 trials carried out on 2,260 adolescents in the United States “demonstrated 100 per cent efficacy and robust antibody responses”, the companies said in a statement.

“We plan to submit these data to (US regulator) FDA as a proposed amendment to our Emergency Use Authorisation in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year,” said Pfizer chief executive Albert Bourla.

Chief executive of German company BioNTech said the results showing high protection for teens were “very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant”.

The BioNTech/Pfizer shot is based on novel mRNA technology and was the first Covid-19 vaccine to be approved in the West late last year.

Both the United States and the European Union have approved its use for people aged 16 and above.

Since then, it has been used in millions of adults in more than 65 countries.

A real world study involving 1.2 million people in Israel found it to be 94 per cent effective.

With the world scrambling to inoculate, BioNTech said Tuesday it was on track to manufacture 2.5 billion doses of its vaccine this year.

The higher output was driven by the recent launch of a new production site in the German city of Marburg, which is now one of the world’s largest mRNA vaccine manufacturing plants, it said.

The vaccine is also being produced at a Pfizer plant in Belgium and at three sites in the United States.

BioNTech said improved efficiency and new cooperation agreements with outside partners had also helped lift its vaccine target, as had the regulatory nod allowing vaccinators to extract six instead of just five doses from a single BioNTech/Pfizer vial.

BioNTech and Pfizer last week began studies of the jab on children, with the first group of 5 to 11-year-olds getting the vaccine.

A younger cohort of 2 to 5-year-olds are expected to get their first dose next week in the study which will also cover children as young as six months old.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

PM Modi calls for united global efforts to defeat COVID pandemic

Statewide curfew in Maharashtra for 15 days from April 14: Maha CM

COVID-19: Karnataka logs 8,778 new cases, 67 deaths push toll past 13,000 mark

TTD booklet to prove Lord Hanuman was ‘born’ in Tirumala Hills to be released on Apr 21

COVID-19 second wave worrying; some states need to ramp up RT-PCR tests: Centre

Panic buying in Mumbai ahead of Maharashtra CM’s announcement

Remdesivir not for home use, meant for serious patients, says Govt amid rise in demand





Related Articles More

COVID-19: Karnataka logs 8,778 new cases, 67 deaths push toll past 13,000 mark

COVID-19 second wave worrying; some states need to ramp up RT-PCR tests: Centre

UK variant more transmissible, but does not increase Covid severity: Lancet studies

Need to provide incentives to COVID-19 vaccine manufacturers to ramp up production: FICCI

COVID-19 pandemic ‘long way from over,’ says WHO chief

MUST WATCH

Boy kills minor Girl for rejecting his Proposal | CRIME FILE

ಲಾಕ್ ಡೌನ್ ಮಾಡುವ ಪ್ರಮೇಯವಿಲ್ಲ: ಸಿಎಂ ಯಡಿಯೂರಪ್ಪ ಸ್ಪಷ್ಟನೆ

CD Victim’s Released Video | Udayavani

Jayalaxmi Silks Udyavara | Glorious Bridal Kanchipuram Sarees Unboxing

News bulletin 12- 04-2021 | UDAYAVANI

Latest Additions

PM Modi calls for united global efforts to defeat COVID pandemic

Statewide curfew in Maharashtra for 15 days from April 14: Maha CM

COVID-19: Karnataka logs 8,778 new cases, 67 deaths push toll past 13,000 mark

TTD booklet to prove Lord Hanuman was ‘born’ in Tirumala Hills to be released on Apr 21

COVID-19 second wave worrying; some states need to ramp up RT-PCR tests: Centre

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.